{"id":"NCT04523142","sponsor":"Novaliq GmbH","briefTitle":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004","officialTitle":"A Phase 3, Multi-center, Open-label, Single-arm Clinical Trial to Assess the Long-term Safety and Tolerability of Topical CyclASolÂ® for the Treatment of Dry Eye Disease in Subjects Who Completed the Clinical Trial CYS-004","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-01-04","primaryCompletion":"2022-04-30","completion":"2022-05-23","firstPosted":"2020-08-21","resultsPosted":"2023-10-16","lastUpdate":"2023-10-16"},"enrollment":202,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Disease (DED)"],"interventions":[{"type":"DRUG","name":"CyclASol Ophthalmic Solution","otherNames":[]}],"arms":[{"label":"CyclASol Ophthalmic Solution","type":"EXPERIMENTAL"}],"summary":"The objective of this trial is to evaluate safety and tolerability of CyclASol during long-term use in subjects with Dry Eye Disease.","primaryOutcome":{"measure":"Number of Subjects Reporting Any Adverse Events","timeFrame":"12 months","effectByArm":[{"arm":"CyclASol Ophthalmic Solution","deltaMin":97,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":["38771801"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":200},"commonTop":["Instillation site pain"]}}